# Ipamorelin – 10mg/vial (Research Use Only)

## Overview

Backed by the Research [Read: How Incretin and Growth-Hormone-Axis Compounds in the Literature →](https://portaltowellness.net/research/glp1-adjunct-peptide-research-guide/)

Ipamorelin is a well-characterized synthetic pentapeptide growth hormone secretagogue (GHS) and selective agonist at the GHSR-1a (ghrelin receptor). Ipamorelin is distinguished in published pharmacology literature by its selective GHSR-1a agonism without meaningful co-stimulation of ACTH, cortisol, or prolactin — a selectivity profile that makes it a widely used reference compound in research isolating GH-specific signaling from broader neuroendocrine effects.

## What It Is

Ipamorelin is a synthetic pentapeptide (5 amino acids) GH secretagogue with the sequence Aib-His-D-2Nal-D-Phe-Lys-NH₂ and a molecular weight of approximately 711 Da. It is a selective agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a), the endogenous receptor for ghrelin. Published pharmacology characterization distinguished Ipamorelin from GHRP-2, GHRP-6, and hexarelin by its lack of significant corticotrope or prolactin cell stimulation in pituitary cell culture systems.

## Research Spotlight

Ipamorelin’s pharmacology research history is grounded in foundational radioligand binding and functional assay studies establishing its GHSR-1a affinity, intrinsic efficacy, and selectivity profile. Published pituitary cell culture studies documented concentration-dependent GH release without meaningful cortisol or ACTH co-secretion — the key selectivity finding that differentiated Ipamorelin from earlier GH secretagogues. In vivo GH pulse pharmacology research in rodent and porcine models has documented dose-response relationships, plasma GH peak timing, and GH pulse amplitude parameters in both single-administration and multi-administration study designs. The Ipamorelin/CJC-1295 (No DAC) combination has been documented as a model for studying synergistic GH pulse amplification through simultaneous GHRH receptor and ghrelin receptor co-stimulation. IGF-1 axis response research following Ipamorelin administration has been published across multiple animal model contexts.

## Key Research Applications

- GHSR-1a receptor binding, affinity, and selectivity characterization
- Selective GH secretagogue pharmacology — isolated from ACTH/cortisol confounders
- Dose-response modeling of pulsatile GH release in rodent and porcine models
- Combination GH secretagogue research (Ipamorelin + CJC-1295 synergy studies)
- Comparative GHSR-1a agonist research vs. GHRP-2, GHRP-6, hexarelin
- IGF-1 axis downstream response measurement in animal models
- GH secretagogue pharmacokinetic characterization
- Pituitary somatotroph cell selectivity and receptor internalization studies

*For laboratory research use only. Not intended for human or veterinary use, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting.*

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

### Related research (educational)

- [Overlapping Pathways in Circadian, Repair and Mitochondrial Biology](https://portaltowellness.net/research/sleep-repair-energy-one-system/)

---

Source: https://portaltowellness.net/shop/ipamorelin-10mg/
Research use only. Terms: https://portaltowellness.net/research-use-only/